|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.798 USD | +5.44% |
|
-8.96% | +71.96% |
| Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
| Apr. 11 | Top Premarket Gainers | MT |
Lipocine Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 0.5 million compared to USD 16.14 million a year ago. Net loss was USD 10.76 million compared to USD 0.634399 million a year ago.
Basic loss per share from continuing operations was USD 2.04 compared to USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 2.21 compared to USD 0.17 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +71.96% | 25.5M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
LIPOCINE INC. 
